Big Biotech Biogen is venturing into the city, paying $16 million in cash to partner up with an RNAi company to build ...

ADARx Pharmaceuticals will work with AbbVie to make RNA interference medicines for a variety of disease areas, including ...

Biogen and City Therapeutics are collaborating to develop select RNAi therapies in a $46 million partnership. City Therapeutics, a private biopharmaceutical company, will offer its RNAi-engineering ...

A start-up that launched only 8 months ago has attracted the attention of Biogen, a major developer of neurological drugs.

Fungal antiviral responses involve three known mechanisms: RNA interference (RNAi), a post-transcriptional mechanism that inhibits viral replication; transcriptional reprogramming; and recognition ...

Forbes contributors publish independent expert analyses and insights. A mega-merger of two convenience store giants looks to have taken a step closer after the Tokyo-based owner of 7-Eleven ...

Biotech major Biogen (Nasdaq: BIIB) and fellow Cambridge, USA-based City Therapeutics, today announced a strategic collaboration to develop select novel RNA interference (RNAi)-based therapies.

Bio­gen is div­ing in­to the RNAi field with City Ther­a­peu­tics, a biotech led by sev­er­al for­mer Al­ny­lam lead­ers.